Liang Xufei, Wang Yueying, Yin Xi, Gong Xiaohong, Pan Shuo, Chen Ziliang, Geng Xuhong
Department of Function, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Graduate School of Medicine, Tianjin Medical University, Tianjin 300070, China.
Cardiol Res Pract. 2020 Dec 9;2020:6678503. doi: 10.1155/2020/6678503. eCollection 2020.
Patients receiving chemotherapy for breast cancer may be at risk of developing cardiac dysfunction and electrophysiological abnormalities. The aim of this study is to evaluate alterations in electrocardiographic (ECG) parameters in breast cancer patients receiving chemotherapy.
This was a prospective single-center cohort study conducted in the Fourth Hospital of Hebei Medical University, China. Participants with breast cancer referred for chemotherapy from May 1, 2019, to October 1, 2019, were invited to participate in the study. Standard 12-lead ECG and echocardiography were performed at baseline or before chemotherapy (prechemotherapy) (T0), after 1 cycle (T1), after 3 cycles (T2), and at the end of chemotherapy (T3).
A total of 64 patients with diagnosed breast cancer undergoing chemotherapy were included. Echocardiographic parameters showed no significant variation during the entire procedure (all > 0.05). The incidence of abnormal ECG increased from 43.75% at baseline to 65.63% at the end of chemotherapy, of which only the prevalence of fragmented QRS (fQRS) was significantly increased after the drug regimen (26.56% to 53.13%). At the end of the treatment, heart rate, P-wave dispersion, corrected QT interval, T-peak to T-end, RR, SV1, RV5, Sokolow-Lyon index (SLI), and index of cardioelectrophysiological balance deteriorated markedly (all < 0.05). The area under the curve for SLI and QT dispersion (QTd) derived by ECG was 0.710 and 0.606, respectively. The cutoff value with 2.12 of SLI by ECG had a sensitivity of 67.2% and specificity of 71.9% for differentiating patients after therapy from baselines. The cutoff value with 0.55 of QTd had a sensitivity of 60.9% and specificity of 60.9%.
The current study demonstrated that ECGs can be used to detect electrophysiological abnormalities in breast cancer patients receiving chemotherapy. ECG changes can reflect subclinical cardiac dysfunction before the echocardiographic abnormalities.
接受乳腺癌化疗的患者可能有发生心脏功能障碍和电生理异常的风险。本研究的目的是评估接受化疗的乳腺癌患者心电图(ECG)参数的变化。
这是一项在中国河北医科大学第四医院进行的前瞻性单中心队列研究。邀请了2019年5月1日至2019年10月1日因化疗前来就诊的乳腺癌患者参与本研究。在基线或化疗前(化疗前)(T0)、1个周期后(T1)、3个周期后(T2)以及化疗结束时(T3)进行标准12导联心电图和超声心动图检查。
共纳入64例确诊为乳腺癌且正在接受化疗的患者。超声心动图参数在整个过程中无显著变化(均P>0.05)。心电图异常的发生率从基线时的43.75%增加到化疗结束时的65.63%,其中仅药物治疗后碎裂QRS波(fQRS)的患病率显著增加(从26.56%增至53.13%)。治疗结束时,心率、P波离散度、校正QT间期、T峰至T末间期、RR间期、SV1、RV5、索科洛夫-里昂指数(SLI)和心脏电生理平衡指数均显著恶化(均P<0.05)。心电图得出的SLI和QT离散度(QTd)的曲线下面积分别为0.710和0.606。心电图得出的SLI为2.12时的截断值区分治疗后患者与基线患者的敏感性为67.2%,特异性为71.9%。QTd为0.55时的截断值敏感性为60.9%,特异性为60.9%。
本研究表明,心电图可用于检测接受化疗的乳腺癌患者的电生理异常。心电图变化可在超声心动图异常之前反映亚临床心脏功能障碍。